Press Releases

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) --

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all those who purchased or otherwise acquired Lyft, Inc. (NASDAQ: LYFT) common stock between February 13, 2024 at 4:05 p.m. and February 13, 2024 at 4:51 p.m. Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada.

For more information, submit a form, email attorney Aaron Dumas, Jr., or... (continue reading...)

Company reports GAAP diluted earnings per share of $1.06 for the quarter; affirms 2024 earnings guidance and $500 million capital investment plan; and announces a $0.65 per share quarterly dividend payable June 28, 2024

BUTTE, Mont. and SIOUX FALLS, S.D., April 25, 2024 (GLOBE NEWSWIRE) -- NorthWestern Energy Group, Inc. d/b/a NorthWestern Energy (Nasdaq: NWE) reported financial results for the three months ended March 31, 2024. Net income for the period was $65.1... (continue reading...)

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all stockholders who purchased or otherwise acquired HireRight Holdings Corp. (NYSE: HRT) securities pursuant to or traceable to the Offering Documents issued in connection with the Company’s October 2021 initial public offering ("IPO"). HireRight provides technology-driven workforce risk management and... (continue reading...)

MONTR�AL, April 25, 2024 (GLOBE NEWSWIRE) -- Bombardier announces that all nominees in its management proxy circular dated March 8, 2024, were elected as directors of Bombardier Inc. during its annual general meeting of shareholders held earlier today. Detailed results of the ballot for the election of directors are below.

Election of Directors Following a vote, each of the following 13 candidates proposed by management was elected a director of Bombardier:

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380... (continue reading...)